Tondi Resta I, Nelson ND, Toorens E, Bleiweiss IJ, Nayak A. Mucinous Cystadenocarcinomas of the Breast Exhibit Heterogeneous Genomic Profile as Triple Negative Breast Cancer, Harbor Alterations in PIK3CA, PTEN, AKT1, and GNAS Genes, and May Not Be Indolent. , Int J Surg Pathol. : 2025
Narasimhamurthy M, Le A, Boruah N, Moses R, Kelly G, Bleiweiss I, Maxwell KN, Nayak A. Clinicopathologic Features of Breast Tumors in Germline TP53 Variant-Associated Li-Fraumeni Syndrome. , Am J Surg Pathol., 49(3): 2025,195-205
Kaitlin Demarest, Arravinth Anantharajah, Kara N. Maxwell1, Mersedeh Rohanizadegan, Angela Bradbury, Katherine L Nathanson, Susan Domchek, Anupma Nayak, Payal D. Shah Pathogenic Germline Variants in Patients with Metaplastic Breast Cancer , JAMA Network Open
, 8(2): 2025
Young AJ, Pantel AR, Kiani M, Doot RK, Bagheri S, Pryma DA, Farwell MD, Li S, Lee H, Schubert EK, Secreto A, Zuckerman SP, Nayak A, Choi H, Carlin S, DeMichele A, Mankoff DA, Zhou R, Mach RH, McDonald ES. Kinetic Analysis and Metabolism of Poly(Adenosine Diphosphate-Ribose) Polymerase-1-Targeted 18F-Fluorthanatrace PET in Breast Cancer. , J Nucl Med. , 65((12)): 2024,1862-68
Li X, Nguyen TTA, Zhang J, Nayak A, Liu Y, Duckworth LA, Zhang G, Bakkar R, Agarwal I, Hou Y, Guo H, Huang X, Wei S, Yasmeen S, Thaer K, Huang H, Zhang H, Smith GH, Turashvili G, Peng L, Liu Y, Yang W, Siziopikou KP. Validation Study of the Newly Proposed Refined Diagnostic Criteria for Malignant Phyllodes Tumor With 136 Borderline and Malignant Phyllodes Tumor Cases , Am J Surg Pathol, 48(9): 2024,1146-1153
Tchou J, Gottipati S, Goldbach M, Baxter M, Venters S, Chen Y, Gonzalves D, Ahmad Z, Nayak A, Mukhtar R, Boughey J. Change in Biomarker Profile after neoadjuvant chemotherapy is prognostic and is especially common in patients with HER2+ breast cancer. , Annals of Surgical Oncology: 2024
Boruah N, Hoyos D, Moses R, Hausler R, Desai H, Le AN, Good M, Kelly G, Raghavakaimal A, Tayeb M, Narasimhamurthy M, Doucette A, Gabriel P, Feldman MJ, Park J, de Rodas ML, Schalper KA, Goldfarb SB, Nayak A, Levine AJ, Greenbaum BD, Maxwell KN. Distinct genomic and immunologic tumor evolution in germline TP53-driven breast cancers.
, bioRxiv [Preprint].: 2024
Ito K, Harada I, Martinez C, Sato K, Lee E, Port E, Byerly JH, Nayak A, Tripathi E, Zhu J, Irie HY. MARCH2, a Novel Oncogene-regulated SNAIL E3 Ligase, Suppresses Triple-negative Breast Cancer Metastases.
, Cancer Res Commun., 28(4): 2024,946-957
Wineland D, Le AN, Hausler R, Kelly G, Barrett E, Desai H, Wubbenhorst B, Pluta J, Bastian P, Symecko H, D'Andrea K, Doucette A, Gabriel P, Reiss KA, Nayak A, Feldman M, Domchek SM, Nathanson KL, Maxwell KN; Regeneron Genetics Center; Penn Medicine Biobank. Biallelic BRCA loss and homologous recombination deficiency in non-breast/ovarian tumors in germline BRCA1/2 carriers , JCO Precision Oncology: 2023
Thacker G, Henry S, Nandi A, Debnath R, Singh S, Nayak A, Susnik B, Boone MM, Zhang Q, Kesmodel SB, Gumber S, Das GM, Kambayashi T, Dos Santos CO, Chakrabarti R. Immature natural killer cells promote progression of triple-negative breast cancer. , Sci Transl Med, 15(686): 2023
